Glaukos (GKOS) Earning Somewhat Positive Media Coverage, Study Finds
News stories about Glaukos (NYSE:GKOS) have been trending somewhat positive recently, according to Accern. Accern identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Glaukos earned a daily sentiment score of 0.11 on Accern’s scale. Accern also assigned news articles about the medical instruments supplier an impact score of 45.2158582409742 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Here are some of the media stories that may have impacted Accern Sentiment Analysis’s analysis:
- Glaukos’ (GKOS) Buy Rating Reiterated at BMO Capital Markets (americanbankingnews.com)
- Why SCANA, Glaukos, and Juno Therapeutics Slumped Today (finance.yahoo.com)
- Glaukos Corporation (GKOS) Receives Consensus Recommendation of “Buy” from Brokerages (americanbankingnews.com)
- Glaukos (GKOS) & The Competition Head-To-Head Comparison (americanbankingnews.com)
Shares of Glaukos (NYSE:GKOS) opened at $25.90 on Wednesday. The stock has a market cap of $897.32, a price-to-earnings ratio of 216.33 and a beta of 1.02. Glaukos has a 52 week low of $23.08 and a 52 week high of $52.49.
Glaukos (NYSE:GKOS) last announced its quarterly earnings data on Tuesday, November 7th. The medical instruments supplier reported $0.04 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.02) by $0.06. The business had revenue of $40.41 million for the quarter, compared to the consensus estimate of $38.69 million. Glaukos had a negative net margin of 0.64% and a positive return on equity of 3.50%. Glaukos’s quarterly revenue was up 36.6% on a year-over-year basis. During the same quarter last year, the company posted $0.03 earnings per share. equities research analysts forecast that Glaukos will post -0.03 earnings per share for the current fiscal year.
Several equities research analysts have recently issued reports on the stock. BidaskClub downgraded shares of Glaukos from a “hold” rating to a “sell” rating in a research note on Saturday, August 26th. BMO Capital Markets restated a “buy” rating on shares of Glaukos in a research note on Monday. Stifel Nicolaus restated a “buy” rating on shares of Glaukos in a research note on Thursday, September 14th. Zacks Investment Research downgraded shares of Glaukos from a “hold” rating to a “sell” rating in a research note on Wednesday, September 20th. Finally, Piper Jaffray Companies restated a “buy” rating and issued a $38.00 price objective on shares of Glaukos in a research note on Friday, September 15th. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. Glaukos currently has an average rating of “Buy” and a consensus target price of $46.57.
In other news, CFO Joseph E. Gilliam bought 2,100 shares of Glaukos stock in a transaction that occurred on Wednesday, November 22nd. The stock was purchased at an average cost of $23.84 per share, with a total value of $50,064.00. Following the completion of the transaction, the chief financial officer now directly owns 102,100 shares in the company, valued at $2,434,064. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 16.40% of the stock is owned by company insiders.
Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.
Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with Analyst Ratings Network's FREE daily email newsletter.